Evidence map›Paper›PMID 39989790›Full record

ArticleACS omega2025

Preparation and Characterization of an Engineered FGF1 Conjugated to

Linlin Song, Michal Kostas, Jon K Laerdahl, Marie Skálová, Tereza Janská, Asta Juzeniene, Svein Ræstad, Alexander Krivokapic, Georgios N Kalantzopoulos, Jaroslav Soltes and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Practical Aspects ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Linlin SongDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway.
Michal KostasDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway.
Jon K LaerdahlDepartment of Microbiology, Oslo University Hospital, Rikshospitalet, Oslo 0424, Norway.
Marie SkálováFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, Prague 1 110 00, Czech Republic.
Tereza JanskáFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, Prague 1 110 00, Czech Republic.
Asta JuzenieneDepartment of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo, 0379 Norway.
Svein RæstadDepartment of Tracer Technology, Institute of Energy Technology, Instituttveien 18, Kjeller 2007, Norway.
Alexander KrivokapicDepartment of Tracer Technology, Institute of Energy Technology, Instituttveien 18, Kjeller 2007, Norway.
Georgios N KalantzopoulosDepartment of Tracer Technology, Institute of Energy Technology, Instituttveien 18, Kjeller 2007, Norway.
Jaroslav SoltesCentrum výzkumu Řež s.r.o., Hlavní 130, Řež, Husinec 250 68, Czech Republic.
Martin VlkFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, Prague 1 110 00, Czech Republic.
Jan KozempelFaculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Břehová 7, Prague 1 110 00, Czech Republic.ORCID https://orcid.org/0000-0002-6315-9225
Sindre HassfjellThor Medical, Karenslyst allé 9C, Oslo 0278, Norway.
Jørgen WescheDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Montebello, Oslo 0379, Norway.ORCID https://orcid.org/0000-0002-9200-9162

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fibroblast growth factor receptor family members, FGFR1-4, are frequently overexpressed in various solid tumors, including breast cancer and sarcomas. This overexpression highlights the potential of the family of FGFRs as promising targets for cancer therapy. However, conventional FGFR kinase inhibitors often encounter challenges such as limited efficacy or drug resistance. In this study, we pursue an alternative strategy by designing a conjugate of the FGFR ligand FGF1 with the radioisotope

Identifiers

PMID39989790
PMCPMC11840634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.